Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...

Atomoxetine is a potent central norepinephrine uptake inhibitor, currently marketed for treatment of attention-deficit/hyperactivity disorder (ADHD). With the ...

Nov. 27, 2002 — Once-daily atomoxetine (Strattera) is effective for children and adolescents with attention deficit hyperactivity disorder (ADHD), according to the results of a randomized, ...

Review the side-effects of Atomoxetine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Atomoxetine (Attentrol (25 mg)) is a selective norepinephrine reuptake inhibitor (SNRI), prescribed for Attention deficit hyperactivity disorder (ADHD). It increases the level of norepinephrine in the ...

Recent evidence suggests that the cognitive symptoms of nicotine withdrawal and the cognitive symptoms of attention deficit hyperactivity disorder (ADHD) may share neural correlates. Thus, ...

Stimulant drugs and another medication – atomoxetine – appear to be the best treatment for managing symptoms of ADHD, a study suggests. Monique Wüstenhagen/dpa Talking therapy and brain stimulation ...

Reason for posting: As a nonstimulant, atomoxetine is a popular new treatment for attention-deficit hyperactivity disorder (ADHD). However, the US Food and Drug Administration and Health Canada ...

There are two main types of medication for ADHD — stimulants, and non-stimulants: Here are the types of non-stimulant medications, how they work, and some common side effects. Why opt for ...

Contrary to popular belief, non-stimulant ADHD medications (atomoxetine and viloxazine) affect heart rate and blood pressure just as much as stimulants do. All ADHD medications except guanfacine ...

NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and ...

Liège, Belgium – 24 October 2023 – 7AM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs ...